The present invention provides UTI fusion proteins, DNA sequences for producing the same, and pharmaceutical compositions and methods of using the same.

Compositions and methods are disclosed that relate to novel plasmin-inhibiting polypeptides that are structural variants of a human TFPI-2 Kunitz-type proteinase first inhibitor domain (8KD1). The polypeptides are potent plasmin inhibitors have antifibrinolytic activity and/or decreased anti-coagulation activity relative to wild-type TFPI-2 KD1. The plasmin-inhibiting polypeptides are useful as anti-cancer agents, as antifibrinolytic agents, as protease inhibitors, as well as in other contexts.

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.

The present invention relates to an inhibitory peptide capable of disrupting a Heparanase/Tissue Factor complex. The invention further provides methods and kits for determining heparanase procoagulant activity in a biological sample. The invention also relates to diagnostic methods for the detection and/or monitoring of a coagulation-related pathologic disorder in a mammalian subject. The invention further relates to compositions comprising heparanase and at least one tissue factor, uses and methods based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions. The invention still further relates to methods for screening a coagulation modulatory compound, methods and uses based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions.

Provided are methods and compositions comprising ulinastatin polypeptides for treating diseases associated with elevated neutrophil elastase (NE), including NE-associated lung and skin diseases.

Described herein are methods for quantifying IAIP levels in a sample.

The present invention relates to a composition for gene manipulation for artificially manipulating a blood coagulation inhibitory gene present in the genome of a cell to regulate a blood coagulation system. More particularly, the present invention relates to a composition for gene manipulation, which includes a guide nucleic acid capable of targeting a blood coagulation inhibitory gene, and an editor protein. Also, the present invention relates to a method of treating or improving coagulopathy using the composition for gene manipulation for artificially manipulating a blood coagulation inhibitory gene.

The present invention relates to a novel peptide that can stimulate the release of cytokines, as well as to the use of the peptide as a medicament.

Provided are ulinastatin glycoforms, ulinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing ulinastatin polypeptides and treating diseases.

Disclosed is a fusion protein including an Ixodes ricinus salivary gland polypeptide. In particular, it relates to a fusion protein including at least one Ixodes ricinus salivary gland polypeptide, at least one serum albumin polypeptide and at least one linker peptide. Also disclosed is the use of such a fusion protein for preventing or treating thrombus formation and/or thrombus growth, as well as pharmaceutical compositions, medicaments and methods including such a fusion protein.